00:00Fatty liver disease is one of the fastest growing liver problems, and the most severe form, called MASH, has very
00:07few treatment options.
00:08Now, researchers at Michigan Medicine report that an experimental drug may tackle it from an unexpected place, the gut.
00:16The compound is called DT109, a tiny 3-amino acid molecule, in mice and in non-human primates.
00:23It reduced a harmful gut bacterium called Clostridium perfringens and lowered ammonia production in the intestine.
00:30It also strengthened the gut barrier, so fewer microbial products leaked toward the liver.
00:35In the primates, which are closer to humans, liver inflammation and MASH severity went down.
00:41The lead author says it has great potential as a treatment, but here is the part that matters most.
00:46So far, this is only animal research.
00:49No human results have been reported, and safety and effectiveness in people are unknown.
00:54The next step is clinical trials.
00:56The university and one researcher also hold a stake in the company developing the drug, which is worth knowing.
01:03Watch for human data.
01:04Disclosure. This video contains stock footage and content created or enhanced using AI-assisted tools.
